1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag

New investigator-initiated study on chronic rhinitis shows positive results with K.O.S treatment from Chordate

The investigator-initiated study The effect of single kinetic oscillation stimulation treatment on nonallergic rhinitis from the University of Helsinki was published in March 2023 and the results show that Chordate's K.O.S treatment provides patients with non-allergic rhinitis with a subjective symptom improvement for at least 1 year, thus possibly decreasing the need for invasive treatment methods.

"This is another investigator-initiated study that, completely independent of Chordate, shows good results one year after rhinitis treatment with K.O.S. The study results show that K.O.S significantly reduced symptoms for a significant proportion of the 49 patients who participated in the study. This is, of course, another important proof that the treatment can help many people around the world who suffer from chronic rhinitis," says Anders Weilandt, CEO of Chordate.

The study was published in the scientific journal Laryngoscope Investigative Otolaryngology and is the fourth publication in the author Sara Sainio's doctoral thesis Efficacy and Safety of Novel Medical Devices in Rhinology.

Read more about the completed, ongoing, and planned studies on the K.O.S treatment

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
New investigator-initiated study on chronic rhinitis shows positive results with K.O.S treatment from Chordate

Datum 2023-05-12, kl 10:55
Källa MFN
Bifogade filer
New investigator-initiated study on chronic rhinitis shows positive results with K.O.S treatment from Chordate
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!